Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

• ClinicalTrials.gov Identifier: NCT02432235
• Recruitment Status: Completed
• First Posted: May 4, 2015
• Results First Posted: July 13, 2021
• Last Update Posted: July 13, 2021
• Sponsor: ADC Therapeutics S.A.
• Information provided by (Responsible Party): ADC Therapeutics S.A.

Study Description

Brief Summary:

This study evaluates camidanlumab tesirine in participants with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma.

Condition or disease	Intervention/treatment	Phase
Hodgkin Lymphoma; Non-Hodgkin Lymphoma	Drug: Camidanlumab tesirine	Phase 1

Detailed Description:

This is a Phase I, first in human clinical study with camidanlumab tesirine to evaluate the safety and tolerability and pharmacokinetics of camidanlumab tesirine in participants with relapsed/refractory lymphoma.

Camidanlumab tesirine is a human monoclonal antibody attached via a cleavable linker to a pyrrolobenzodiazepine (PBD) warhead which, when internalized by antigen expressing cells, covalently cross links deoxyribonucleic acid (DNA) preventing replication.

The study will be conducted in 2 parts: Part 1 (dose escalation) and Part 2 (expansion).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 133 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
• Actual Study Start Date: October 5, 2015
• Actual Primary Completion Date: October 24, 2019
• Actual Study Completion Date: October 24, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: 3 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 5 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 8 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 13 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 20 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 30 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 45 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 60 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 80 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 100 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 150 μg/kg; Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami
Experimental: 300 μg/kg; A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles).	Drug: Camidanlumab tesirine; Intravenous (IV) infusion.; Other Names: ADCT-301; Cami

Outcome Measures

Primary Outcome Measures :

1. Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) [ Time Frame: Cycle 1 Day 1 to end of Cycle 1 or 2 (21 day cycle length) ]

   A DLT defined as any of the following, except those that are clearly due to underlying disease or extraneous causes:

   A hematologic DLT is defined as (different considerations for Adult T-Cell Leukemia/Lymphoma (ATLL) participants):

   • Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 febrile neutropenia or neutropenic infection
   • CTCAE Grade 4 neutropenia lasting >7 days
   • CTCAE Grade 4 thrombocytopenia
   • CTCAE Grade 3 thrombocytopenia with clinically significant bleeding, or Grade 3 thrombocytopenia requiring a platelet transfusion
   • CTCAE Grade 4 anemia

   A non-hematologic DLT is defined as:

   • CTCAE Grade 4 tumor lysis syndrome
   • CTCAE Grade 3 or higher AE (including nausea, vomiting, diarrhea, electrolyte imbalances lasting ≥ 48 hours despite optimal therapy; excluding all grades of alopecia)
   • CTCAE Grade 3 or higher hypersensitivity reaction
   • CTCAE Grade 2 or higher skin ulceration
   • CTCAE Grade 2 or higher peripheral sensory or motor neuropathy
2. Recommended Dose of Camidanlumab Tesirine for Part 2 [ Time Frame: Cycle 1 Day 1 to end of Cycle 1 or 2 (21 day cycle length) ]
   The recommended dose was established by the dose escalation steering committee and based on safety findings during Part 1 of the study.
3. Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE) [ Time Frame: Day 1 up to 84 days after last dose (median time on treatment was 43 days [min 1 day; max 354 days]) ]
   An adverse event (AE) is defined as any untoward medical occurrence in a participant enrolled into this study regardless of its causal relationship to study drug. A TEAE is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug.
4. Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE) [ Time Frame: Day 1 up to 84 days after last dose (median time on treatment was 43 days [min 1 day; max 354 days]) ]
   A treatment-emergent AE (TEAE) is defined as any event not present before exposure to study drug or any event already present that worsens in either intensity or frequency after exposure to study drug. An SAE is defined as any event that results in death, is immediately life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

Secondary Outcome Measures :

1. Overall Response Rate (ORR) [ Time Frame: Day 1 to End of Study (a maximum of 12 months after treatment; median time on treatment was 43 days [min 1 day; max 354 days]) ]

   ORR is defined as the number of participants with a best overall response of complete response (CR) or partial response (PR) at the time each participant discontinued treatment with camidanlumab tesirine.

   Tumor response was assessed using the 2014 Lugano Classification.

   CR is defined as achieving each of the following:

   • Complete metabolic response.
   • Complete radiologic response (target node regress to <1.5 cm, no nonmeasured lesions, no organ enlargement, no new lesions and normal bone marrow morphology).

   PR is defined as achieving each of the following:

   • Partial metabolic response (findings indicate residual disease).
   • Partial remission (>50% decrease in target measurable nodes, regression/ absence/ no increase of nonmeasured lesions, spleen regressed by >50% in length and no new lesions).
2. Duration of Response (DoR) [ Time Frame: Day 1 to End of Study (a maximum of 12 months after last dose; median time on treatment was 43 days [min 1 day; max 354 days]) ]

   DoR is defined among responders (complete response [CR] and partial response [PR]) as the time from the earliest date of first response until the first date of either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification.

   Disease progression is defined as progressive metabolic disease and one of the follow:

   • Target node progression.
   • An individual extranodal lesion must be abnormal with length > 1.5cm and/or increase of length > 50%.
   • New or clear progression of nonmeasured lesions.
   • Regrowth of previously resolved lesions or new nodes >1.5 cm in length.
   • New or recurrent bone marrow involvement.

   DoR is presented overall for all participants who were classed as responders among the efficacy analysis set. Data is pooled for all lymphoma participants for DoR as specified in protocol section 8.4.

3. Progression-Free Survival (PFS) [ Time Frame: Day 1 to End of Study (a maximum of 12 months after last dose; median time on treatment was 43 days [min 1 day; max 354 days]) ]

   Progression-free survival (PFS) is defined among the efficacy population as the time from first dose of study drug until either disease progression or death due to any cause. Tumor response was assessed using the 2014 Lugano Classification for response.

   Disease progression is defined as progressive metabolic disease and one of the following:

   • Target node progression.
   • An individual extranodal lesion must be abnormal with length > 1.5cm and/or increase of length > 50%.
   • New or clear progression of nonmeasured lesions.
   • Regrowth of previously resolved lesions or new nodes > 1.5 cm in length.
   • New or recurrent bone marrow involvement.

   PFS is presented overall for all participants who received camidanlumab tesirine among the efficacy analysis set. Data is pooled for all lymphoma participants for PFS as specified in protocol section 8.4

4. Overall Survival (OS) [ Time Frame: Day 1 to End of Study (a maximum of 12 months after last dose; median time on treatment was 43 days [min 1 day; max 354 days]) ]

   Overall survival (OS) is defined as the time from the first dose of study drug treatment until the date of death due to any cause.

   OS is presented overall for all participants who received camidanlumab tesirine among the efficacy analysis set. Data is pooled for all lymphoma participants for OS as specified in protocol section 8.4.

5. Maximum Observed Serum Concentration (Cmax) for Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycles 1 and 2 (21 day cycle length) ]
   Cmax for HuMax-TAC, pyrrolobenzodiazepine (PBD) conjugated HuMax-TAC, and free warhead (SG3199).
6. Time to Reach the Maximum Serum Concentration (Tmax) for Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycles 1 and 2 (21 day cycle length) ]
   Tmax for HuMax-TAC, PBD-conjugated HuMax-TAC, and free warhead (SG3199).
7. Area Under the Serum Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) for Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycles 1 and 2 (21 day cycle length) ]
   AUC0-last for HuMax-TAC, PBD-conjugated HuMax-TAC, and free warhead (SG3199).
8. Area Under the Serum Concentration-time Curve From Time 0 to the End of the Dosing Interval (AUC0-t) for Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycle 2 (21 day cycle length) ]
   AUC0-tau for HuMax-TAC, PBD-conjugated HuMax-TAC, and free warhead (SG3199) for Cycle 2 only.
9. Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUC∞) for Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycle 1 (21 day cycle length) ]
   AUC∞ HuMax-TAC and PBD-conjugated HuMax-TAC for Cycle 1 only.
10. Accumulation Index (AI) for Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycles 1 and 2 (21 day cycle length) ]
    AI for HuMax-TAC, PBD-conjugated HuMax-TAC, and free warhead (SG3199). AI is the ratio of area under the serum concentration-time curve (AUC) from 0 to 21 days for Cycle 2 divided by AUC from 0 to 21 days for Cycle 1 (21 day cycle length). It is the increase in drug plasma concentration after multiple dosing until a steady state is reached.
11. Volume of Distribution for Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycles 1 and 2 (21 day cycle length) ]
    Volume of distribution for HuMax-TAC, PBD-conjugated HuMax-TAC, and free warhead (SG3199).
12. Apparent Terminal Half-life (T1/2) of Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycles 1 and 2 (21 day cycle length) ]
    T1/2 of HuMax-TAC, PBD-conjugated HuMax-TAC, and free warhead (SG3199).
13. Clearance of Camidanlumab Tesirine [ Time Frame: Pre-dose on Day 1 and 1 to 336 hours post-dose of Cycles 1 and 2 (21 day cycle length) ]
    Clearance of HuMax-TAC, PBD-conjugated HuMax-TAC, and free warhead (SG3199).
14. Number of Participants With Anti-drug Antibody Response (ADA) Against Camidanlumab Tesirine [ Time Frame: Day 1 to End of Study (a maximum of 12 months after last dose; median time on treatment was 43 days [min 1 day; max 354 days]) ]
    An assay determines the presence of anti-ADCT-301 antibodies in human serum using a validated bridging electro chemiluminescence immunoassay (ECLIA) technique. The technique uses the drug itself to capture any anti ADCT-301 antibodies present in the serum. If anti-ADCT-301 antibodies are detected, they are confirmed to be specifically against ADCT-301 and then the level of the anti-ADCT-301 antibodies present in the serum is established using a modified version of the ECLIA technique.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female age 18 years or older.
2. Refractory or relapsed lymphoma (per World Health Organization (WHO) Classification system)
3. Pathologically confirmed relapsed or refractory lymphoma
4. Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block.
5. Measurable disease, defined by the 2014 Lugano Classification Criteria and Global Response Score Grading Scales for cutaneous T-cell lymphoma (CTCL)
6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
7. Absolute neutrophil count ≥1500/µL. Criterion not applicable to adult T cell leukemia/lymphoma (ATLL) patients.
8. Platelet count of ≥75000/µL. Criterion not applicable to ATLL patients.
9. Hemoglobin ≥9.0 g/dL without transfusion within the 2 weeks prior to Day 1.
10. Serum/plasma creatinine ≤1.5 mg/dL, or if the participant has a creatinine > 1.5 mg/dL, a measured creatinine clearance must be > 80 mL/min as calculated by the Cockcroft and Gault equation
11. Serum alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase ≤2 times the upper limit of normal (ULN); ≤ 5 times ULN if there is liver or bone involvement.
12. Total serum/plasma bilirubin ≤1.5 times ULN (participants with known Gilbert's syndrome may have a total bilirubin up to ≤3 times ULN)
13. Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test within 7 days prior to Day 1.
14. Women of childbearing potential must agree to use a highly effective method of contraception. Men with female partners who are of childbearing potential must agree that they or their partners will use a highly effective method of contraception.

Exclusion Criteria:

1. Participants who have an option for any treatment with proven clinical benefit for their lymphoid malignancy at current state of disease.
2. Active graft-versus-host disease.
3. Autologous or allogenic transplant within the 60 days prior to Cycle 1 Day 1 (C1D1)
4. Evidence of myelodysplasia or myeloid leukemia by morphology, immunostains, flow cytometry, or cytogenetics on a bone marrow aspirate or biopsy.
5. Known history of positive serum human anti-drug antibody (ADA) or known allergy to any component of ADCT-301.
6. History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjögren's syndrome, autoimmune vasculitis [e.g., Wegener's granulomatosis])
7. History of neuropathy considered of autoimmune origin (e.g., polyradiculopathy including Guillain-Barré syndrome and myasthenia gravis); other central nervous system autoimmune disease (e.g., poliomyelitis, multiple sclerosis).
8. History of recent infection (within 4 weeks of C1D1) considered to be caused by one of the pathogens listed: herpes simplex virus Type 1 (HSV1), herpes simplex virus Type 2 (HSV2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), measles, Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni, or enterovirus D68.

9. Known seropositive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus (anti-HCV) with confirmatory testing and requiring anti-viral therapy. Note: testing is not mandatory to be eligible.

   If participant is at risk for having undiagnosed hepatitis C virus (HCV) (e.g., history of injection drug use), HCV testing should be considered.

10. History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
11. Pregnant or breastfeeding women.
12. Significant medical comorbidities, including uncontrolled hypertension (diastolic blood pressure > 115 mm Hg), unstable angina, congestive heart failure (greater than New York Heart Association class II), severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, poorly controlled diabetes, severe chronic pulmonary disease, coronary angioplasty, or myocardial infarction within 6 months prior to screening, or uncontrolled atrial or ventricular cardiac arrhythmias.
13. Use of any other experimental medication(s) within 14 days or 5 half-lives, but in no case < 14 days prior to the start of study treatment on Cycle 1, Day 1, except if approved by the Sponsor.
14. Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy (including prednisone ≥ 40 mg/day or equivalent) within 14 days or 5 half-lives (whichever is shorter) prior to Cycle 1, Day 1 treatment, except if approved by the Sponsor.
15. Failure to recover (to Common Terminology Criteria for Adverse Events [CTCAE Version 4.0] Grade 0 or Grade 1) from acute non-hematologic toxicity (except all grades of alopecia or Grade 2 or lower neuropathy), due to previous therapy, prior to Screening.
16. Congenital long QT syndrome or a corrected QT interval (QTc)≥ 450 ms at screening (unless secondary to pacemaker or bundle branch block).
17. Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that Sponsor Medical Monitor and Investigator agree, and document should not be exclusionary.
18. Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgment, make the participant inappropriate for study participation or put the participant at risk.

Contacts and Locations

Locations

United States, California

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, California, United States, 91010

United States, New York

Memorial Sloan-Kettering Cancer Center

New York, New York, United States, 10065

United States, Ohio

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States, 44106

United States, Texas

The University of Texas/MD Anderson Cancer Center

Houston, Texas, United States, 77030-4009

Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States, 78229

United States, Virginia

Virginia Cancer Specialists, PC

Fairfax, Virginia, United States, 22031

United States, Wisconsin

Froedtert Hospital/Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

United Kingdom

Guy's and St. Thomas' Hospital NHS Trust

London, England, United Kingdom, SE1 9RT

The Newcastle Upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, England, United Kingdom

Churchill Hospital, Oxford University Hospitals NHS Foundation Trust

Oxford, England, United Kingdom, OX3 7LE

The Christie NHS Foundation Trust

Manchester, Greater Manchester, United Kingdom, M20 4BX

Southampton General Hospital, University Hospital Southampton NHS Foundation Trust

Southampton, Hampshire, United Kingdom

Sponsors and Collaborators

ADC Therapeutics S.A.

Investigators

• Study Director: Jens Wuerthner, MD, PhD; ADC Therapeutics

  Study Documents (Full-Text)

Documents provided by ADC Therapeutics S.A.:

Study Protocol  [PDF] January 4, 2019

Statistical Analysis Plan  [PDF] March 24, 2020

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Toukam M, Wuerthner J, Havenith K, Hamadani M, Caimi PF, Kopotsha T, Cruz HG, Boni JP. Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2023 Jan;91(1):13-24. doi: 10.1007/s00280-022-04486-4. Epub 2022 Nov 4.

Toukam M, Boni JP, Hamadani M, Caimi PF, Cruz HG, Wuerthner J. Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2023 Jan;91(1):1-12. doi: 10.1007/s00280-022-04487-3. Epub 2022 Nov 4.

Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A, Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 2021 Jun;8(6):e433-e445. doi: 10.1016/S2352-3026(21)00103-4.

• Responsible Party: ADC Therapeutics S.A.
• ClinicalTrials.gov Identifier: NCT02432235
• Other Study ID Numbers: ADCT-301-001; 2015-005272-25 ( EudraCT Number ); 199948 ( Registry Identifier: HRA )
• First Posted: May 4, 2015
• Results First Posted: July 13, 2021
• Last Update Posted: July 13, 2021
• Last Verified: July 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by ADC Therapeutics S.A.:

Camidanlumab tesirine

Additional relevant MeSH terms:

Lymphoma; Lymphoma, Non-Hodgkin; Hodgkin Disease; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases